They examined the fibroblast-myofibroblast and endothelial-mesenchymal transitions in cell cultures and found that the serum from SSc patient’s treatment, up-regulated levels of type I collagen, α-smooth muscle actin (α-SMA) and related genes, whereas in healthy control serum no changes were found. This evidence concerns the gene ACTA1 and systemic sclerosis.